autologous IL-7Ra-expressing Tris-CAR T cells

A preparation of autologous T lymphocytes that have been genetically modified and lentivirally transduced to express a dual-target chimeric antigen receptor (CAR) and a truncated form of the cytokine receptor interleukin-7 (IL-7) receptor alpha (IL-7Ra), with potential immunostimulating and antineoplastic activities. Upon administration, autologous IL-7Ra-expressing Tris-CAR T cells target and bind to tumor cells expressing the targets, thereby inducing selective toxicity in these tumor cells. In addition, as IL-7/IL-7Ra-mediated signaling promotes the proliferation and survival of T cells, these tumor re-directed T cells may show enhanced expansion, survival and cytotoxicity.